Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy. (PubMed, Allergy) - Oct 1, 2026 - "Compared to placebo, abatacept did not suppress the allergen-related induction of peanut-specific IgE relative to their total at 24 weeks, but improved OIT tolerability in this severely allergic adult population. Independently of abatacept, most participants achieved sustained unresponsiveness with OIT."
Clinical • Journal • Allergy • Food Hypersensitivity • Immunology • CTLA4
|
|
Anne Des Roches; Camille Braun; Eloïse Antony; Emilie Roy; Florence Gingras-Lessard; François Graham; Kathryn Samaan; Louis Paradis; Marie-Ève Gingras; Marie-Lee Simard; Philippe Bégin; Roxane Labrosse; Thomas Eiwegger
|